Haemonetics (HAE) Cash from Investing Activities (2016 - 2025)
Haemonetics has reported Cash from Investing Activities over the past 17 years, most recently at -$29.5 million for Q4 2025.
- For Q4 2025, Cash from Investing Activities fell 69.63% year-over-year to -$29.5 million; the TTM value through Dec 2025 reached -$74.9 million, up 61.19%, while the annual FY2025 figure was -$161.9 million, 49.78% up from the prior year.
- Cash from Investing Activities for Q4 2025 was -$29.5 million at Haemonetics, up from -$30.5 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $18.0 million in Q1 2025 and troughed at -$429.1 million in Q2 2021.
- A 5-year average of -$61.8 million and a median of -$27.3 million in 2023 define the central range for Cash from Investing Activities.
- Biggest five-year swings in Cash from Investing Activities: tumbled 850.7% in 2021 and later surged 238.17% in 2025.
- Year by year, Cash from Investing Activities stood at -$20.5 million in 2021, then crashed by 77.88% to -$36.5 million in 2022, then tumbled by 636.81% to -$268.9 million in 2023, then surged by 93.54% to -$17.4 million in 2024, then crashed by 69.63% to -$29.5 million in 2025.
- Business Quant data shows Cash from Investing Activities for HAE at -$29.5 million in Q4 2025, -$30.5 million in Q3 2025, and -$33.0 million in Q2 2025.